| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 74.240 | 18.543 | 5.995 | 15.329 | 15.423 | 150.168 | 0 | 5.607 | 14.189 | 0 |
| Total Income - EUR | 93.346 | 50.525 | 16.994 | 40.681 | 275.927 | 333.493 | 23.247 | 86.613 | 14.595 | 0 |
| Total Expenses - EUR | 38.509 | 3.400 | 3.904 | 32.864 | 31.859 | 231.193 | 22.998 | 28.511 | 33.970 | 0 |
| Gross Profit/Loss - EUR | 54.837 | 47.125 | 13.091 | 7.816 | 244.068 | 102.300 | 249 | 58.102 | -19.375 | 0 |
| Net Profit/Loss - EUR | 48.047 | 45.609 | 12.837 | 7.410 | 241.308 | 98.965 | 45 | 57.254 | -19.521 | 0 |
| Employees | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 0 |
Check the financial reports for the company - Rx Innovations Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.103 | 427 | 139 | 67 | 63.263 | 43 | 42 | 43 | 42 | 42 |
| Current Assets | 95.713 | 71.108 | 31.602 | 24.814 | 203.641 | 140.268 | 100.421 | 138.108 | 75.410 | 74.989 |
| Inventories | 44 | 0 | 0 | 0 | 2.094 | 0 | 0 | 29 | 141 | 140 |
| Receivables | 94.765 | 54.325 | 21.867 | 16.111 | 192.265 | 135.755 | 95.131 | 137.817 | 55.934 | 55.621 |
| Cash | 904 | 16.783 | 9.735 | 8.703 | 9.282 | 4.513 | 5.290 | 262 | 19.335 | 19.227 |
| Shareholders Funds | 48.103 | 45.665 | 12.892 | 20.065 | 260.985 | 99.017 | 96.838 | 57.305 | -12.931 | -12.859 |
| Social Capital | 47 | 47 | 46 | 45 | 44 | 43 | 42 | 43 | 42 | 42 |
| Debts | 48.712 | 25.870 | 18.849 | 4.862 | 5.934 | 41.304 | 3.626 | 80.967 | 88.415 | 87.921 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Rx Innovations Srl